Presentation and Status in Health Basket
Presentation | Basket | Yarpa | Pharmasoft |
---|---|---|---|
Film Coated Tablets 28 x 50 mg |
|||
Film Coated Tablets 56 x 50 mg |
|||
Film Coated Tablets 28 x 100 mg |
|||
Film Coated Tablets 56 x 100 mg |
|||
Film Coated Tablets 56 x 200 mg |
Dosage
The usual starting dosage is generally one tablet of 50 mg or 100 mg twice a day. The recommended target dosage is generally 200 mg twice a day.
Indications
Treatment of heart failure (NYHA class II-IV) in patients with systolic dysfunction.
This medicinal product has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ACE) inhibitor therapy.
Contra-Indications
* Hypersensitivity to the active substances or to any of the excipients.
* Concomitant use with ACE inhibitor. Wait 36 hours after taking the last ACEI dose before starting treatment with this medical product.
* Known history of angioedema related to ACE inhibitor or an angiotensin receptor blocker (ARB) therapy, hereditary or unknown cause.
* Concomitant use with aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment.
* Severe liver disease.
* Second and third trimester of pregnancy.
Special Precautions
Please refer to the license holder for further details.
Side Effects
Very common: Cough, dizziness, diarrhea, low levels of red blood cells, tiredness, acute renal failure, hypokalemia, headache, fainting, weakness, nausea, orthostatic hypotension, gastritis, spinning sensation, hypoglycemia.
Common: Hypotension, hyperkalemia, renal impairment.
Please refer to the license holder for further details.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details
Overdose
Please refer to the license holder for further details